Published in Genetics and Environmental Business Week, February 2nd, 2006
B.S. Malaeb and colleagues, University of Minnesota, wrote that the purpose of the study was "to evaluate the cause and significance of elevated aPTT in a group of patients who received a first-generation adenoviral vector (Ad-OC-TK) delivering a toxic gene to prostate cancer cells as part of a Phase I clinical trial at the University of Virginia."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.